Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Nature Publishes Work Utilizing N-Gene’s Core Technology to Advance the Treatment of Duchenne Muscular Dystrophy

April 18, 2012

NEW YORK, April 19, 2012 /PRNewswire/ — N-Gene Research Laboratories, Inc. (“N-Gene”), today announces that Australian scientists in close cooperation with N-Gene have shown that BGP-15, a heat shock protein inducer, may be a novel therapy for treating the deadly, rare disease, Duchenne Muscular Dystrophy (DMD), as recently reported in the journal Nature.

Currently there is no cure and no adequate therapy for DMD. BGP-15 was not only able to make a key protein functional again, thereby reducing muscle damage, but also increase the strength and endurance, and ultimately the lifespan, of DMD animals.

“This pioneering work strengthens N-Gene’s role at the forefront of heat shock protein science,” said Gabor K. Kalman, chief executive officer of N-Gene.

Peter Literati, Ph.D., co-founder and chief scientific officer of N-Gene said, “We believe this publication reinforces the expectation that N-Gene’s platform technology, based on stress-response regulation, will eventually result in the emergence of a novel drug class with diverse therapeutic directions. We are remaining focused on advancing BGP-15 for the treatment of type 2 diabetes, but we look forward to seeking partners with which to advance this technology and realize its potential in the treatment of DMD as well as many other disease indications.”

Dr. Literati will be speaking at a news event today in Budapest, Hungary, to discuss the data described above, the publication and the potential for N-Gene compounds to treat DMD and many other diseases.

About N-Gene Research Laboratories

N-Gene Research Laboratories, Inc. (“N-Gene”), is a biopharmaceutical research company with a pipeline of proprietary drugs to treat insulin-resistance syndrome, improve cancer chemotherapy and target other major disease classes. BGP-15, N-Gene’s lead compound, is a co-inducer of HSP-72 that increases insulin sensitivity via blocking JNK phosphorylation. Results from a defining international Phase 2b study of BGP-15 in patients with type 2 diabetes are expected by the end of 2012.

For more information please visit http://www.ngene.us.

    Media Contacts                      Corporate Contact
    --------------                      -----------------
    Tony Russo, Ph.D.                   Gabor K Kalman
    Matt Middleman, M.D.                Chief Executive Officer
    Russo Partners                      T: (212)-605-0225
    T: 212-845-4251                     kalmang@ngene.us
    T: 212-845-4272
    tony.russo@russopartnersllc.com
    matt.middleman@russopartnersllc.com

SOURCE N-Gene Research Laboratories, Inc.


Source: PR Newswire